| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
1 |
| Antineoplastic Drug |
0 |
0.95 |
| Advanced and Metastatic Breast Cancer |
0 |
0.74 |
| Humanized Monoclonal Antibody |
0 |
0.69 |
| Antibody Drug Conjugates |
0 |
0.47 |
| Hodgkin Lymphoma |
0 |
0.46 |
| Triple Negative Breast Cancer |
0 |
0.43 |
| Cancer |
0 |
0.42 |
| Chemotherapy |
0 |
0.37 |
| Breast |
0 |
0.28 |
| Genomic Medicine |
0 |
0.28 |
| Receptors |
0 |
0.19 |
| Epidermal Growth Factor Receptor |
0 |
0.17 |
| Clinical Research |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Adjuvant Therapy |
0 |
0.05 |
| Adverse Effects |
0 |
0.05 |
| Estrogen |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Monoclonal Antibody |
0 |
0.05 |
| Patient Safety |
0 |
0.05 |
| Taxane |
0 |
0.05 |
| Tumor |
0 |
0.05 |